FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
(WorldNews Japan)

Issued: 25 September 2020, London UK Third US indication for Nucala demonstrates GSK`s commitment to finding new ways to help patients with eosinophil-driven diseases GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US. Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: `HES is a...